サンプル依頼リスト カート
  • English
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1766574

ゾレドロン酸市場：適応症別、投与経路別、容量別、年齢層別、性別、製品タイプ別、エンドユーザー別、地域別

Zoledronic Acid Market, By Indication, By Route of Administration, By Dosage Strength, By Age Group, By Gender, By Product Type, By End User, By Geography

出版日
ページ情報
英文 165 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=150.05円
ゾレドロン酸市場：適応症別、投与経路別、容量別、年齢層別、性別、製品タイプ別、エンドユーザー別、地域別
出版日: 2025年06月27日
発行: Coherent Market Insights
ページ情報: 英文 165 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

ゾレドロン酸市場は、2025年に53億8,000万米ドルと推定され、2032年には76億2,000万米ドルに達すると予測され、2025年から2032年までの年間平均成長率（CAGR）は5.1%で成長すると予測されています。

レポート範囲 レポート詳細
基準年 2024 2025年の市場規模 53億8,000万米ドル
実績データ 2020年から2024年まで 予測期間 2025年から2032年
予測期間：2025年～2032年CAGR： 5.10% 2032年の価値予測 76億2,000万米ドル

ゾレドロン酸の世界市場は、製薬業界の中でも重要なセグメントであり、主に骨関連の疾患や合併症の治療に利用される強力なビスフォスフォネート医薬品に焦点を当てています。ゾメタやリクラストなど、さまざまな商品名で販売されているゾレドロン酸は、破骨細胞を介した骨吸収を阻害する窒素含有ビスホスホネートとして機能し、骨粗鬆症、ページェット病、さまざまながんに伴う骨転移などの病態管理に不可欠な薬剤です。この薬のユニークな作用機序は、鉱化骨マトリックスに結合し、ファルネシルピロリン酸合成酵素を阻害することで、破骨細胞の機能を効果的に破壊し、骨密度の維持を促進することです。世界中のヘルスケアシステムが人口の高齢化と骨関連病態の増加に取り組む中、ゾレドロン酸のような効果的な治療介入に対する需要は増加の一途をたどっています。同市場には、病院投与用の点滴製剤やさまざまな治療適応に特化した製剤など、さまざまな製剤があります。ドラッグデリバリーシステムの最近の進歩は、従来の骨疾患以外の臨床応用の拡大と相まって、ゾレドロン酸を、世界の多様なヘルスケア環境において大きな市場潜在力を持つ汎用性の高い治療薬として位置づけています。

市場力学

ゾレドロン酸の世界市場は、いくつかの強力な促進要因によって支えられています。その主な促進要因は、急速に高齢化が進む世界人口であり、骨粗鬆症、骨折、および関連合併症に対する感受性の高まりが、効果的な骨強化療法に対する大きな需要を生み出しています。特に、骨への転移が多い乳がん、前立腺がん、肺がんの有病率の上昇は、ゾレドロン酸が骨格関連事象の予防や悪性腫瘍による高カルシウム血症の管理に重要な介入を行うことから、市場の成長を大きく後押ししています。さらに、骨の健康管理の重要性に関する医療従事者や患者の意識の高まりと、骨障害の早期発見のための診断能力の向上が、治療採用率の上昇に寄与しています。しかし、市場は顎骨壊死、心房細動、腎合併症などの潜在的な副作用を含む顕著な抑制要因に直面しており、これらは長期的な治療プロトコルに関して医師と患者の双方にためらいを生じさせています。ビスフォスフォネート製剤の承認に関する厳しい規制要件は、専門的なヘルスケア環境を必要とする静脈内投与の複雑さと相まって、市場参入のさらなる障壁となっています。さらに、他のビスフォスフォネート系薬剤、デノスマブ、新たな骨標的治療薬などの代替治療オプションが利用可能になり、競合圧力が強まっています。とはいえ、希少骨疾患の治療への応用拡大、他の抗がん剤との併用療法の可能性、患者のコンプライアンスを改善し投与の複雑さを軽減する新規デリバリーメカニズムの開発などを通じて、大きなビジネスチャンスが生まれています。新興市場におけるヘルスケアインフラの成長、医療費の増加、骨の健康に対する意識向上キャンペーンは、世界中のゾレドロン酸メーカーおよび販売業者にとって、未開拓の市場ポテンシャルを大きく示しています。

本調査の主な特徴

  • 本レポートでは、世界のゾレドロン酸市場を詳細に分析し、2024年を基準年とした予測期間（2025-2032年）の市場規模（10億米ドル）と年間平均成長率（CAGR%）を掲載しています。
  • さまざまなセグメントにわたる潜在的な収益機会を明らかにし、この市場の魅力的な投資提案のマトリックスについて解説しています。
  • また、市場促進要因、抑制要因、機会、新製品の上市や承認、市場動向、地域別の展望、主要企業が採用する競争戦略などに関する主要考察も提供しています。
  • 本レポートでは、ゾレドロン酸の世界市場における主要企業を、企業ハイライト、製品ポートフォリオ、主要なハイライト、業績、戦略などのパラメータに基づいてプロファイルしています。
  • 本レポートからの洞察により、マーケティング担当者や企業の経営陣は、将来の製品発売、タイプアップ、市場拡大、マーケティング戦術に関する情報に基づいた意思決定を行うことができます。
  • ゾレドロン酸の世界市場レポートは、投資家、サプライヤー、製品メーカー、流通業者、新規参入者、財務アナリストなど、この業界のさまざまな利害関係者を対象としています。
  • 利害関係者は、世界のゾレドロン酸市場を分析する際に使用される様々な戦略マトリックスを通じて、意思決定を容易にすることができます。

目次

第1章 調査の目的と前提条件

  • 調査目的
  • 前提条件
  • 略語

第2章 市場の展望

  • レポートの説明
    • 市場の定義と範囲
  • エグゼクティブサマリー

第3章 市場力学、規制、動向分析

  • 市場力学
  • 促進要因
  • 抑制要因
  • 機会
  • 影響分析
  • 主な発展
  • 規制シナリオ
  • 製品の発売/承認
  • PEST分析
  • PORTERの分析
  • 合併と買収のシナリオ
  • 業界動向

第4章 ゾレドロン酸の世界市場、適応症別、2020年～2032年

  • 骨粗鬆症の治療と予防
  • 閉経後骨粗鬆症
  • 腫瘍学関連の適応症
  • 骨転移
  • その他（骨パジェット病、小児骨形成不全症（適応外使用）など）

第5章 ゾレドロン酸の世界市場、投与経路別、2020年～2032年

  • 静脈内注入
  • 経口投与

第6章 ゾレドロン酸の世界市場、用量別、2020年～2032年

  • 4 mg/100 mLの使い捨てボトル
  • 4 mg/5 mLの使い捨てバイアル
  • 100 mLの輸液溶液に5 mgを添加

第7章 世界のゾレドロン酸市場、年齢層別、2025年～2032年

  • 高齢者
  • 成人

第8章 ゾレドロン酸の世界市場、性別、2020年～2032年

  • 女性
  • 男性

第9章 世界のゾレドロン酸市場、製品タイプ別、2020年～2032年

  • ブランドゾレドロン酸
  • ジェネリックゾレドロン酸

第10章 世界のゾレドロン酸市場、エンドユーザー別、2020年～2032年

  • 病院と専門クリニック
  • がん治療センター
  • 外来手術センター（ASC）
  • 長期ケア施設
  • その他（調査機関等）

第11章 世界のゾレドロン酸市場、地域別、2020年～2032年

  • 北米
      • 米国
      • カナダ
  • ラテンアメリカ
      • ブラジル
      • アルゼンチン
      • メキシコ
      • その他ラテンアメリカ
  • 欧州
      • ドイツ
      • 英国
      • スペイン
      • フランス
      • イタリア
      • ロシア
      • その他欧州
  • アジア太平洋
      • 中国
      • インド
      • 日本
      • オーストラリア
      • 韓国
      • ASEAN
      • その他アジア太平洋地域
  • 中東
      • GCC諸国
      • イスラエル
      • その他中東
  • アフリカ
      • 南アフリカ
      • 北アフリカ
      • 中央アフリカ

第12章 競合情勢

  • Novartis AG
  • Teva Pharmaceutical Industries Ltd.
  • Amgen Inc.
  • Eli Lilly and Company
  • Merck & Co., Inc.
  • Sanofi S.A.
  • GSK（GlaxoSmithKline）
  • Roche Holding AG
  • Pfizer Inc.
  • Bayer AG
  • AbbVie Inc.
  • Johnson & Johnson
  • Astellas Pharma Inc.
  • Ashfield Healthcare
  • Hikma Pharmaceuticals plc

第13章 アナリストの推奨事項

  • 機会
  • アナリストの見解
  • Coherent Opportunity Map

第14章 参考文献と調査手法

  • 参考文献
  • 調査手法
  • 出版社について
目次
Product Code: CMI8167

Zoledronic Acid Market is estimated to be valued at USD 5.38 Bn in 2025 and is expected to reach USD 7.62 Bn by 2032, growing at a compound annual growth rate (CAGR) of 5.1% from 2025 to 2032.

Report Coverage Report Details
Base Year: 2024 Market Size in 2025: USD 5.38 Bn
Historical Data for: 2020 To 2024 Forecast Period: 2025 To 2032
Forecast Period 2025 to 2032 CAGR: 5.10% 2032 Value Projection: USD 7.62 Bn

The global zoledronic acid market represents a critical segment within the pharmaceutical industry, focusing on a potent bisphosphonate medication primarily utilized for treating bone-related disorders and complications. Zoledronic acid, marketed under various brand names including Zometa and Reclast, functions as a nitrogen-containing bisphosphonate that inhibits osteoclast-mediated bone resorption, making it essential for managing conditions such as osteoporosis, Paget's disease, and bone metastases associated with various cancers. The medication's unique mechanism of action involves binding to mineralized bone matrix and inhibiting farnesyl pyrophosphate synthase, effectively disrupting osteoclast function and promoting bone density preservation. As healthcare systems worldwide grapple with aging populations and increasing incidences of bone-related pathologies, the demand for effective therapeutic interventions like zoledronic acid continues to escalate. The market encompasses various formulations including intravenous solutions for hospital administration and specialized preparations for different therapeutic indications. Recent advancements in drug delivery systems, coupled with expanding clinical applications beyond traditional bone disorders, have positioned zoledronic acid as a versatile therapeutic agent with significant market potential across diverse healthcare settings globally.

Market Dynamics

The global zoledronic acid market is propelled by several compelling drivers, with the primary catalyst being the rapidly aging global population that inherently faces increased susceptibility to osteoporosis, bone fractures, and related complications, creating substantial demand for effective bone-strengthening therapies. The rising prevalence of cancer, particularly breast, prostate, and lung cancers that frequently metastasize to bones, significantly drives market growth as zoledronic acid serves as a crucial intervention for preventing skeletal-related events and managing hypercalcemia of malignancy. Additionally, growing awareness among healthcare professionals and patients about the importance of bone health management, coupled with improved diagnostic capabilities for early detection of bone disorders, contributes to increased treatment adoption rates. However, the market faces notable restraints including potential adverse effects such as osteonecrosis of the jaw, atrial fibrillation, and renal complications, which create hesitancy among both physicians and patients regarding long-term treatment protocols. Stringent regulatory requirements for bisphosphonate approvals, coupled with the complexity of intravenous administration requiring specialized healthcare settings, pose additional barriers to market accessibility. Furthermore, the availability of alternative treatment options including other bisphosphonates, denosumab, and emerging bone-targeting therapies intensifies competitive pressure. Nevertheless, significant opportunities emerge through expanding applications in treating rare bone diseases, potential combination therapies with other anticancer agents, and development of novel delivery mechanisms that could improve patient compliance and reduce administration complexity. The growing healthcare infrastructure in emerging markets, combined with increasing healthcare expenditure and awareness campaigns about bone health, presents substantial untapped market potential for zoledronic acid manufacturers and distributors worldwide.

Key Features of the Study

  • This report provides in-depth analysis of the global zoledronic acid market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global zoledronic acid market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Novartis AG, Teva Pharmaceutical Industries Ltd., Amgen Inc., Eli Lilly and Company, Merck & Co., Inc., Sanofi S.A., GSK (GlaxoSmithKline), Roche Holding AG, Pfizer Inc., Bayer AG, AbbVie Inc., Johnson & Johnson, Astellas Pharma Inc., Ashfield Healthcare, and Hikma Pharmaceuticals plc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global zoledronic acid market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global zoledronic acid market

Market Segmentation

  • Indication Insights (Revenue, USD Bn, 2020 - 2032)
    • Osteoporosis Treatment & Prevention
    • Postmenopausal Osteoporosis
    • Male Osteoporosis
    • Glucocorticoid-Induced Osteoporosis
    • Oncology-Related Indication
    • Bone Metastases
    • Breast
    • Prostate
    • Lung Cancer
    • Multiple Myeloma
    • Hypercalcemia of Malignancy (HCM)
    • Others (Paget's Disease of Bone, Pediatric Osteogenesis Imperfecta [off-label use], etc.)
  • Route of Administration Insights (Revenue, USD Bn, 2020 - 2032)
    • Intravenous infusion
    • Oral administration
  • Dosage Strength Insights (Revenue, USD Bn, 2020 - 2032)
    • 4 mg/100 mL single-use ready-to-use bottle
    • 4 mg/5 mL single-use vial
    • 5 mg in a 100 mL ready to infuse solution
  • Age Group Insights (Revenue, USD Bn, 2020 - 2032)
    • Geriatric
    • Adult
  • Gender Insights (Revenue, USD Bn, 2020 - 2032)
    • Female
    • Male
  • Product Type Insights (Revenue, USD Bn, 2020 - 2032)
    • Branded Zoledronic Acid
    • Generic Zoledronic Acid
  • End User Insights (Revenue, USD Bn, 2020 - 2032)
    • Hospitals & Specialty Clinics
    • Cancer Treatment Centers
    • Ambulatory Surgical Centers (ASCs)
    • Long-term care facilities
    • Others (Research Institutes, etc.)
  • Regional Insights (Revenue, USD Bn, 2020 - 2032)
    • North America
    • U.S.
    • Canada
    • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
    • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
    • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
    • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
    • Africa
    • South Africa
    • North Africa
    • Central Africa
  • Key Players Insights
    • Novartis AG
    • Teva Pharmaceutical Industries Ltd.
    • Amgen Inc.
    • Eli Lilly and Company
    • Merck & Co., Inc.
    • Sanofi S.A.
    • GSK (GlaxoSmithKline)
    • Roche Holding AG
    • Pfizer Inc.
    • Bayer AG
    • AbbVie Inc.
    • Johnson & Johnson
    • Astellas Pharma Inc.
    • Ashfield Healthcare
    • Hikma Pharmaceuticals plc

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Global Zoledronic Acid Market, By Indication
    • Global Zoledronic Acid Market, By Route of Administration
    • Global Zoledronic Acid Market, By Dosage Strength
    • Global Zoledronic Acid Market, By Age Group
    • Global Zoledronic Acid Market, By Gender
    • Global Zoledronic Acid Market, By Product Type
    • Global Zoledronic Acid Market, By End User
    • Global Zoledronic Acid Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
  • Driver
  • Restraint
  • Opportunity
  • Impact Analysis
  • Key Developments
  • Regulatory Scenario
  • Product Launches/Approvals
  • PEST Analysis
  • PORTER's Analysis
  • Merger and Acquisition Scenario
  • Industry Trends

4. Global Zoledronic Acid Market, By Indication, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Osteoporosis Treatment & Prevention
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Postmenopausal Osteoporosis
    • Male Osteoporosis
    • Glucocorticoid-Induced Osteoporosis
  • Oncology-Related Indication
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Bone Metastases
    • Breast
    • Prostate
    • Lung Cancer
    • Multiple Myeloma
    • Hypercalcemia of Malignancy (HCM)
  • Others (Paget's Disease of Bone, Pediatric Osteogenesis Imperfecta [off-label use], etc.)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

5. Global Zoledronic Acid Market, By Route of Administration, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Intravenous infusion
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Oral administration
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Zoledronic Acid Market, By Dosage Strength, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • 4 mg/100 mL single-use ready-to-use bottle
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • 4 mg/5 mL single-use vial
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • 5 mg in a 100 mL ready to infuse solution
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Zoledronic Acid Market, By Age Group, 2025-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Geriatric
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Adult
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global Zoledronic Acid Market, By Gender, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Female
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Male
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

9. Global Zoledronic Acid Market, By Product Type, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Branded Zoledronic Acid
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Generic Zoledronic Acid
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

10. Global Zoledronic Acid Market, By End User, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Hospitals & Specialty Clinics
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Cancer Treatment Centers
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Ambulatory Surgical Centers (ASCs)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Long-term care facilities
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Others (Research Institutes, etc.)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

11. Global Zoledronic Acid Market, By Region, 2020 - 2032, Value (USD Bn)

  • Introduction
    • Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
    • Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
    • Regional Trends
  • North America
    • Introduction
    • Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Dosage Strength, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Product Type, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
      • U.S.
      • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Dosage Strength, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Product Type, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
      • Brazil
      • Argentina
      • Mexico
      • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Dosage Strength, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Product Type, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
      • Germany
      • U.K.
      • Spain
      • France
      • Italy
      • Russia
      • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Dosage Strength, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Product Type, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
  • Middle East
    • Introduction
    • Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Dosage Strength, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Product Type, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
      • GCC Countries
      • Israel
      • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Dosage Strength, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Product Type, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
      • South Africa
      • North Africa
      • Central Africa

12. Competitive Landscape

  • Novartis AG
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Teva Pharmaceutical Industries Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Amgen Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Eli Lilly and Company
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Merck & Co., Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Sanofi S.A.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • GSK (GlaxoSmithKline)
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Roche Holding AG
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Pfizer Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Bayer AG
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • AbbVie Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Johnson & Johnson
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Astellas Pharma Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Ashfield Healthcare
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Hikma Pharmaceuticals plc
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies

13. Analyst Recommendations

  • Wheel of Fortune
  • Analyst View
  • Coherent Opportunity Map

14. References and Research Methodology

  • References
  • Research Methodology
  • About us